Abstract:Abstract Multiple myeloma promotes systemic skeletal bone disease that greatly contributes to patient morbidity. Resorption of type I collagen–rich bone matrix by activated osteoclasts results in the release of sequestered growth factors that can drive progression of the disease. Matrix metalloproteinase-13 (MMP13) is a collagenase expressed predominantly in the skeleton by mesenchymal stromal cells (MSC) and MSC-derived osteoblasts. Histochemical analysis of human multiple myeloma specimens also demonstrated that MMP13 largely localizes to the stromal compartment compared with CD138+ myeloma cells. In this study, we further identified that multiple myeloma induces MMP13 expression in bone stromal cells. Because of its ability to degrade type I collagen, we examined whether bone stromal–derived MMP13 contributed to myeloma progression. Multiple myeloma cells were inoculated into wild-type or MMP13–null mice. In independent in vivo studies, MMP13–null mice demonstrated significantly higher overall survival rates and lower levels of bone destruction compared with wild-type controls. Unexpectedly, no differences in type I collagen processing between the groups were observed. Ex vivo stromal coculture assays showed reduced formation and activity in MMP13–null osteoclasts. Analysis of soluble factors from wild-type and MMP13–null MSCs revealed decreased bioavailability of various osteoclastogenic factors including CXCL7. CXCL7 was identified as a novel MMP13 substrate and regulator of osteoclastogenesis. Underscoring the importance of host MMP13 catalytic activity in multiple myeloma progression, we demonstrate the in vivo efficacy of a novel and highly selective MMP13 inhibitor that provides a translational opportunity for the treatment of this incurable disease. Significance: Genetic and pharmacologic approaches show that bone stromal–derived MMP13 catalytic activity is critical for osteoclastogenesis, bone destruction, and disease progression.

Osteocyte CIITA aggravates osteolytic bone lesions in myeloma

Osteal Tissue Macrophages Are Involved in Endplate Osteosclerosis Through the OSM-STAT3/YAP1 Signaling Axis in Modic Changes

Promotion of Bone Lesions Through the Myeloma Integrin α6-Mediated Osteolytic Signaling

Downregulation of Mir-223 and Mir-19A Induces Differentiation and Promotes Recruitment of Osteoclast Cells in Giant-Cell Tumor of the Bone Via the Runx2/TWIST-RANK/RANKL Pathway

Bacterial infections exacerbate myeloma bone disease

Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma

Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma–Induced Osteolysis and Reduces Overall Survival

m6A reader hnRNPA2B1 drives multiple myeloma osteolytic bone disease

Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1‐targeting miRNA‐92a‐1‐5p

Osteocyte mitochondria inhibit tumor development via STING-dependent antitumor immunity

LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-κB/RELT signal pathway

Mitochondria from osteolineage cells regulate myeloid cell-mediated bone resorption

Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma

Acid-Induced Inflammatory Cytokines in Osteoblasts: A Guided Path to Osteolysis in Bone Metastasis

Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease

[SDF-1/CXCR4 and Multiple Myeloma Osteolytic Bone Lesions--review].

Inhibition of mitochondrial OMA1 ameliorates osteosarcoma tumorigenesis

BIGH3 mediates apoptosis and gap junction failure in osteocytes during renal cell carcinoma bone metastasis progression

The Proteasome and Myeloma-Associated Bone Disease

Matrix metalloproteinases and tissue inhibitors in multiple myeloma: promote or inhibit?